In this video, health care analysts David Williamson and Max Macaluso discuss Vertex's recent tie up with two deep-pocketed members of big pharma. Although Vertex currently owns the standard of care for hepatitis C treatments, it isn't sitting on its laurels. Watch and find out what this new deal means for Vertex, its partners, and its competitors.
A new potential hep-c drug combo takes shape
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid
